• FXR LLPS Organizes Coronavirus Replication Organelles

  2026-09-04

  Li et al. show that fragile X–related proteins organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation, linking condensate biology to replication-organelle architecture. The study identifies FXR-dependent DMV clustering as a host process that supports translation near viral replication sites and efficient SARS-CoV-2 replication.

• Quizartinib (AC220) in FLT3 AML Workflows

  2026-09-04

  Quizartinib (AC220) combines low-nanomolar FLT3 potency with selectivity that supports cleaner pathway attribution in acute myeloid leukemia (AML) research. This guide converts that profile into practical phosphorylation, viability, resistance, and xenograft workflows, with assay controls designed to separate on-target biology from handling artifacts.

• AmpliFold Capture-and-Release for Sensitive LFAs

  2026-09-03

  The AmpliFold strategy addresses a central lateral flow assay bottleneck by separating initial analyte capture from final signal detection. In a HER2 model, triggered release and high-affinity rebinding improved sensitivity while retaining a rapid, equipment-free workflow, although additional validation is needed before general clinical translation.

• Redox-Responsive Peptide Coacervates for mRNA Delivery

  2026-09-03

  Ren and colleagues developed HBpep-SS4, a single-component peptide coacervate that combines high mRNA encapsulation with glutathione-triggered intracellular release. The study shows broad RNA cargo compatibility, efficient cellular delivery, and functional genome editing, while also defining important limitations for translation beyond the tested models.

• QNZ (EVP4593): Applied NF-κB Workflows

  2026-09-02

  QNZ (EVP4593) provides nanomolar inhibition of NF-κB signaling for reporter, cytokine, and neuronal calcium-entry studies. This practical guide connects validated pathway assays with solubility controls, orthogonal readouts, and reproducibility lessons from hospital surveillance research.

• Polymeric Nanoplatform Activates cGAS-STING in TAMs

  2026-09-02

  The 2024 Journal of Controlled Release study developed M-PNP@R@C, a mannose-modified, pH-responsive polymeric nanoplatform that co-delivers R848 and cGAMP to tumor-associated macrophages. The formulation linked macrophage polarization and STING-dependent SIRPα downregulation to enhanced phagocytosis, reduced metastasis with anti-CD47, and improved survival when combined with anti-PD-L1 in preclinical cancer models.

• AS1842856: A Functional Foxo1 Assay Guide

  2026-09-01

  AS1842856 is a specific Foxo1 inhibitor for dissecting transcriptional activity, gluconeogenesis, and autophagy. This guide connects the compound’s metabolic readouts with the iron-sensitive PI3K-Akt-Foxo1 pathway and translates that biology into practical assay decisions.

• S1P/S1PR3 Drives Neuronal Apoptosis After ICH

  2026-09-01

  The reference study identifies an S1P–S1PR3 axis that connects post-hemorrhagic inflammation with neuronal apoptosis through TNF-α, PI3K/AKT-associated signaling, and cleaved caspase-3. By combining a mouse intracerebral hemorrhage model with HT22-cell experiments and pharmacological S1PR3 inhibition, it positions S1PR3 as a mechanistically relevant and potentially targetable component of secondary brain injury.

• LNP Surface Charge and V-ATPase Drive Nucleic Acid Delivery

  2026-08-31

  The reference study proposes that LNP tropism is governed by a synergy between nanoparticle surface charge and the V-ATPase activity of target-cell endo/lysosomal compartments. Its perturbation experiments connect this interaction to liver or lung delivery, reticuloendothelial-system conditioning, and differences in protein corona composition, offering a cell-state-aware framework for nucleic acid delivery design.

• Atorvastatin: HMG-CoA Reductase Inhibitor Research

  2026-08-31

  Atorvastatin is an orally bioavailable HMG-CoA reductase inhibitor used in cholesterol metabolism research, vascular cell biology studies, and cardiovascular disease research. Peer-reviewed 2025 work also supports atorvastatin as a preclinical ferroptosis-inducing candidate in hepatocellular carcinoma, but this finding does not establish clinical cancer efficacy.

• Isochlorogenic Acid A Disrupts the HBV Life Cycle

  2026-08-30

  A 2026 Antiviral Research study shows that isochlorogenic acid A suppresses hepatitis B virus at multiple stages, including transcription, cccDNA maintenance, capsid formation, and envelopment. Its mechanistic model links HO-1 induction and intracellular ROS modulation to altered viral protein chemistry and defective morphogenesis, providing a framework for more discriminating antiviral experiments.

• WST-8 Glucose Uptake Assay Kit for CPP Studies

  2026-08-29

  Connect cell-penetrating peptide and nucleic acid delivery experiments to a fast, non-radioactive measurement of cellular glucose handling. This workflow uses ion-optimization controls and a quantitative WST-8 glucose uptake assay to distinguish delivery-driven metabolic effects from assay interference.

• CCK8, NOX4, and ANP Secretion in Rat Atria

  2026-08-28

  The reference study identifies a sulfated CCK-8–NOX4–PGC-1α–PPARα/PPARγ pathway that links atrial peptide signaling with controlled reactive oxygen species production. Its isolated beating rat atria model provides a useful framework for separating ANP secretion, atrial mechanics, redox signaling, and feedback regulation.

• Hexamethonium Bromide Research Workflows

  2026-08-28

  Use Hexamethonium Bromide to separate autonomic ganglionic transmission from vascular and cardiac effects in neuronal signaling experiments. This workflow translates sex-stratified angiotensin II hypertension findings into practical telemetry, ex vivo, control, and troubleshooting strategies.

• Thiazovivin (A5506): Practical Stem Cell Guide

  2026-08-27

  Thiazovivin is a ROCK inhibitor for in vitro workflows where dissociation-associated cell loss or inefficient fibroblast reprogramming limits results. This guide covers handling, controls, and troubleshooting for stem cell research; it is not a clinical or diagnostic protocol, and no universal working concentration is provided in the product dossier.

8073 records 1/539 page Next 12345 下5页 Last page